Hepatoprotective Properties of New Xymedon Derivatives with a Modified Structural Moiety

We studied the hepatoprotective properties of new modifications of the Russian drug, the regeneration stimulator Xymedon (1,2-dihydro-4,6-dimethyl-1-(2-hydroxyethyl)-pyrimidin-2-one) (1): 1,2-dihydro-4,6-dimethyl-(1-(2-((hydroxyethyl)amino)ethyl)-pyrimidin-2-one (2) and 1,2-dihydro-4,6-dimethyl-1-propyl-pyrimidin-2-one (3). First, cytotoxicity and cytoprotective effects of the compounds were assessed on Chang Liver, HepG2, and WI-38 human cell lines, and then, hepatoprotective activity in vivo was evaluated on the model of toxic CCl₄-induced liver damage in Wistar rats. Compounds (2) and (3) exhibited cytoprotective properties: they increased cell viability against the background of d-galactosamine treatment and reduced the morphological signs of liver damage caused by CCl₄. Compound (3) had significantly higher cytotoxicity. Of the two modifications, compound (2) is more promising for further work.